<DOC>
	<DOCNO>NCT01561391</DOCNO>
	<brief_summary>This trial conduct North America . The aim trial compare safety efficacy activate recombinant human factor VII patient haemophilia A B undergoing major surgical procedure .</brief_summary>
	<brief_title>Safety Efficacy Activated Recombinant Human Factor VII Haemophilia Patients With Inhibitors During After Major Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Have haemophilia A B inhibitor factor VIII IX , respectively Have historical inhibitor level least five Bethesda unit inadequate haemostatic response 250 U/kg factor VIII IX inadequate response FEIBA Require preplanned major surgery hospital Have participate treated investigational drug activate recombinant human factor VII within last thirty day Have treat haemostatic agent , include rFVIIa , within 48 hour preoperative dose Have haemostatic disorder haemophilia</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>